Therapeutic Solutions International, Inc.
TSOI · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.00 | 0.00 | 0.02 |
| FCF Yield | 1.60% | -3.97% | -4.73% | -429.91% |
| EV / EBITDA | -2.88 | -14.59 | -8.73 | -15.44 |
| Quality | ||||
| ROIC | 37,517.99% | -14.47% | -22.80% | -25.74% |
| Gross Margin | 77.58% | 66.37% | 65.66% | -693.91% |
| Cash Conversion Ratio | -0.00 | 0.37 | 0.35 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -29.39% | 385.73% | 397.30% | 461.24% |
| Free Cash Flow Growth | 149.40% | 30.22% | 98.74% | -4,895.71% |
| Safety | ||||
| Net Debt / EBITDA | -0.50 | -3.05 | -1.46 | -2.85 |
| Interest Coverage | -18.43 | -5.46 | -7.55 | -5.79 |
| Efficiency | ||||
| Inventory Turnover | 0.26 | 0.38 | 389.33 | 8.38 |
| Cash Conversion Cycle | -8,093.62 | -4,726.60 | 70.53 | -109.36 |